Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1998-7-24
pubmed:abstractText
The Medical Research Council (MRC) United Kingdom trial for childhood acute lymphoblastic leukaemia (UKALL X) randomised patients aged 0-14 years inclusive with an initial white blood count of less than 100 x 10(9)/l to receive an early intensification block, a late intensification block, both, or neither. The next trial, UKALL XI, for children aged 1-14 years, randomised between different central nervous system (CNS) directed therapies. At the beginning of the trial, all patients were also randomised between late intensification alone and both early plus late blocks. The effects of both the early and the late block in UKALL X alone have been reported previously. This paper examines the effect of the addition of the early intensification block to treatment which included late intensification, combining the data from UKALL X and the first part of UKALL XI. Early intensification was associated with fewer bone marrow relapses and a reduction in the odds of death of 0.63 (95% confidence interval: 0.46-0.87). Survival was significantly improved with an increase at 5 years of 8%, from 79 to 87%. Following this demonstration that early intensification improves survival, the effect of a third intensification block is under investigation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0887-6924
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1031-6
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:9665186-Adolescent, pubmed-meshheading:9665186-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9665186-Asparaginase, pubmed-meshheading:9665186-Child, pubmed-meshheading:9665186-Child, Preschool, pubmed-meshheading:9665186-Combined Modality Therapy, pubmed-meshheading:9665186-Cytarabine, pubmed-meshheading:9665186-Daunorubicin, pubmed-meshheading:9665186-Drug Administration Schedule, pubmed-meshheading:9665186-Etoposide, pubmed-meshheading:9665186-Female, pubmed-meshheading:9665186-Humans, pubmed-meshheading:9665186-Infant, pubmed-meshheading:9665186-Infant, Newborn, pubmed-meshheading:9665186-Male, pubmed-meshheading:9665186-Methotrexate, pubmed-meshheading:9665186-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:9665186-Prednisolone, pubmed-meshheading:9665186-Thioguanine, pubmed-meshheading:9665186-Vincristine
pubmed:year
1998
pubmed:articleTitle
Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia.
pubmed:affiliation
Clinical Trial Service Unit, Oxford, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't